Luxa Biotechnology announces clinical trial results for treatment of AMD

Luxa Biotechnology LLC announced results from its phase 1/2a clinical trial titled “Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes.”¹ The results were published in the journal Cell Stem Cell.

Luxa is a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (AMD).

The main objective of the open-label phase 1/2a clinical trial (NCT04627428) is to evaluate the safety and tolerability of RPESC-RPE-4W as a therapy for dry AMD.² According to the publication in Cell Stem Cell, RPESC-RPE-4W is “a post-mitotic adult RPE stem cell-derived RPE (RPESC-RPE) progenitor cell product.”³

It implants RPESC-RPE-4W cell suspensions in three dose cohorts: cohort 1 (50,000 cells), cohort 2 (150,000 cells), and cohort 3 (250,000 cells).³

Cohort 1, composed of 3 worse-seeing subjects with best-corrected visual acuity (BCVA) of 20/200–20/800, assessed by reading the standardized Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart, completed its low-dose interventions.³ Six subjects received a subretinal suspension of 50,000 RPESC-RPE-4W cells, and no significant inflammation, tumor, or product-related serious adverse events were observed or reported.^1,3 Patients with better baseline vision showed more modest gains (+3.0 letters at 6 months).¹

“The results from cohort 1 demonstrate the potential of RPESC-RPE-4W not only to restore vision in patients with severe vision loss but also to benefit those at earlier stages of diseases,” Keith Dionne, PhD, CEO of Luxa Biotechnology, said in a press release.

Best-corrected visual acuity (BCVA) in the 3 worse-seeing group A subjects improved by an average of +21.67 letters from baseline at 12 months, while 3 better-seeing group B subjects improved by an average of +3.0 letters at 6 months.³ The positive safety and tolerability outcomes for low-dose cohort 1 enabled dose escalation to mid-dose RPESC-RPE-4W therapy for dry AMD, the journal noted.³

“We are excited to continue advancing our clinical program, which recently received regenerative medicine advanced therapy (RMAT) designation from the FDA, as a potential new regenerative therapy for dry AMD, a leading cause of blindness with no currently approved vision-improving treatments,” Dionne said.¹

Reference:

1. Morningstar I. Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy. Morningstar, Inc. Published September 17, 2025. Accessed September 18, 2025. https://www.morningstar.com/news/business-wire/20250917979431/luxa-biotechnology-announces-publication-in-cell-stem-cell-describing-positive-clinical-results-for-first-in-human-clinical-trial-for-dry-amd-therapy

2. Clinicaltrials.gov. Published 2025. Accessed September 18, 2025. https://clinicaltrials.gov/study/NCT04627428?term=NCT04627428&rank=1

3. Rao RC, Arduini BL, Borden S, et al. Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes. Cell Stem Cell. Published online September 2025. doi:https://doi.org/10.1016/j.stem.2025.08.012